Literature DB >> 9092741

Mycosis fungoides with onset before 20 years of age.

H S Zackheim1, T H McCalmont, F W Deanovic, R B Odom.   

Abstract

BACKGROUND: Recent identification of mycosis fungoides (MF) in a man in whom the diagnosis was established at age 22 months prompted us to evaluate our experience with early onset MF.
OBJECTIVE: Our purpose was to summarize the clinical characteristics and course of 24 patients in whom MF began by history before age 20 years and was confirmed by biopsy in 13 by that time.
METHODS: A retrospective study was conducted.
RESULTS: All 24 patients had patch/plaque disease and represented 4.3% of the 557 patients with cutaneous T-cell lymphoma seen by us since 1971. None progressed to a more advanced stage in up to 24 years (median, 12 years) after histologic diagnosis. Five patients (21%) presented with hypopigmentation.
CONCLUSION: Early onset MF is not more aggressive than that appearing in adult life. MF should be considered in the differential diagnosis of chronic dermatoses in young persons, particularly in those presenting with hypopigmentation.

Entities:  

Mesh:

Year:  1997        PMID: 9092741     DOI: 10.1016/s0190-9622(97)70243-3

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

1.  Clinical Outcome and Prognosis of Young Patients with Mycosis Fungoides.

Authors:  Pooja Virmani; Laura Levin; Patricia L Myskowski; Eileen Flores; Michael A Marchetti; Anna Skripnik Lucas; Melissa Pulitzer; Steven Horwitz; Tanya Trippett; Alison Moskowitz; Christiane Querfeld
Journal:  Pediatr Dermatol       Date:  2017-08-14       Impact factor: 1.588

Review 2.  T-cell Lymphoma Epidemiology: the Known and Unknown.

Authors:  Anh Phan; Rachel Veldman; Mary Jo Lechowicz
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  Cutaneous T-cell lymphoma in Saudi Arabia: retrospective single-center review.

Authors:  Yousef Binamer
Journal:  Ann Saudi Med       Date:  2017 May-Jun       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.